Platelet Factor IV, Human, Peptide

Catalog #: HC2139
Quantity: 50 µg
$320.00

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

Description
Details
Platelet factor IV (PF4), also called chemokine ligand 4 (CXCL4) is a heparin-binding protein mainly expressed by platelets and megakaryocytes. PF4 has both procoagulant and anticoagulant activity. By heparin binding it inhibits heparin-dependent thrombin activation. In contrast, it also inhibits factor XII of the contact activation pathway and by generation of activated protein C by thrombomodulin binding. PF4 is a 7.8 kDa protein containing 70 amino acids which is secreted from α-granules by activation in a tetrameric form. Ionic strength and pH play an important role in defining the state of the protein complex. Activation takes place during platelet aggregation and its release promotes blood coagulation. These activities indicate a role in wound repair and inflammation. Furthermore, PF4 has been reported to be involved in numerous processes, including hematopoiesis and angiogenesis inhibition, platelet coagulation interference, and host inflammatory response. PF4 is a non-ELR-CXC chemokine and binds to the CXCR3B receptor found on endothelial cells and activated T-lymphocytes. Alternative sources for PF4 are smooth muscle cells, microglia, macrophages and T-cells. Besides the mentioned processes PF4 is also involved in apoptosis, cell differentiation, survival, and differentiation. Since not all cells involved in these processes express the CXCR3B receptor an alternative should exist. Indeed the molecules also exert their actions via binding to, the negatively charged, glycosaminoglycans (GAG; predominantly chondroitin- and heparan sulfates). PF4 capability to inhibit angiogenesis and to promote innate immune responses made it a widely investigated target in tumor intervention and inflammation. Another main clinical topic is heparin-induced thrombocytopenia (HIT). In these patients the PF4-heparin complex acts as a immunogen leading to PF4/heparin antibodies leading to platelet activation and aggregation, thrombocytopenia and thrombosis. Bacterial infections and increasing antibiotic resistance are still an emerging problem. Therefore new ways to eradicate infections are explored. Antibacterial peptides could aid in this strategy. The last 13 amino acids of the carboxyl terminus of PF4 have been found to be antibacterial. The Platelet factor IV peptide has the following sequence: ALYKKLLKKLLKSAKKLG which is an optimized antibactericidal derivative of the last 13 amino acids of the C-terminal end of the human protein.
Specifications

Specifications

Catalog number HC2139
Product type Proteins
Quantity 50 µg
Species Human
Alias PF4, C-X-C motif chemokine 4, CXCL4, Iroplact, Oncostatin-A
Formulation Lyophilized product in PBS, containing 50 µg Platelet Factor IV. Reconstitute the vial by pipetting distilled or de-ionized water (Caution: vial is under vacuum).
Storage and stability Lyophilized product should be stored at 4°C. Store stock solution in aliquots at -20°C. Repeated freeze and thaw cycles will cause loss of activity. Lyophilized product is stable for at least one year, reconstituted and stored at -20°C, the product is stable for 6 months.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease Cardiology and metabolism
Application
Applications
  • Application:
    FS, W
  • Use:
    For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user’s experimental setting.
Downloads